$ALXO
ALX ONCOLOGY HOLDINGS INC

2022 Q3 Form 10-Q Financial Statement

#000095017022015553 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.299M $7.041M $7.674M
YoY Change 14.73% 38.44% 76.01%
% of Gross Profit
Research & Development $29.38M $26.75M $17.07M
YoY Change 61.32% 138.54% 73.35%
% of Gross Profit
Depreciation & Amortization $95.00K $84.00K $58.00K
YoY Change 1483.33% 8300.0% 1060.0%
% of Gross Profit
Operating Expenses $36.68M $33.79M $24.75M
YoY Change 101.39% 107.31% 74.18%
Operating Profit -$36.68M -$33.79M -$24.75M
YoY Change 101.39% 107.31% 74.18%
Interest Expense $1.370M $876.0K $225.0K
YoY Change -34350.0% 3708.7% 800.0%
% of Operating Profit
Other Income/Expense, Net -$9.000K -$7.000K -$11.00K
YoY Change -164.29% -450.0% 450.0%
Pretax Income -$35.32M -$32.92M -$24.53M
YoY Change 43.78% 102.29% 72.95%
Income Tax
% Of Pretax Income
Net Earnings -$35.32M -$32.92M -$24.53M
YoY Change 43.78% 102.29% 72.95%
Net Earnings / Revenue
Basic Earnings Per Share -$0.87 -$0.81 -$0.60
Diluted Earnings Per Share -$0.87 -$0.81 -$604.0K
COMMON SHARES
Basic Shares Outstanding 40.75M 40.69M 40.63M
Diluted Shares Outstanding 40.75M 40.69M 40.62M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $284.9M $313.4M $316.6M
YoY Change -26.03% -23.56% -26.36%
Cash & Equivalents $49.05M $66.38M $159.1M
Short-Term Investments $235.9M $247.0M $157.5M
Other Short-Term Assets $5.899M $3.481M $4.929M
YoY Change 54.67% 50.5% 97.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $290.8M $316.8M $321.5M
YoY Change -25.24% -23.15% -25.63%
LONG-TERM ASSETS
Property, Plant & Equipment $2.336M $1.630M $1.338M
YoY Change 315.66% 876.05% 2746.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $8.217M $10.86M $25.11M
YoY Change
Other Assets $16.33M $16.68M $15.70M
YoY Change 60.03% 88.59% 2829.85%
Total Long-Term Assets $26.88M $29.17M $42.15M
YoY Change 149.71% 223.69% 7130.02%
TOTAL ASSETS
Total Short-Term Assets $290.8M $316.8M $321.5M
Total Long-Term Assets $26.88M $29.17M $42.15M
Total Assets $317.7M $346.0M $363.7M
YoY Change -20.52% -17.87% -15.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.880M $8.680M $5.133M
YoY Change 59.65% 49.5% -30.16%
Accrued Expenses $18.97M $14.84M $9.746M
YoY Change 126.48% 91.67% 260.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $393.0K $429.0K $429.0K
YoY Change -8.39% 0.0% 329.0%
Total Short-Term Liabilities $25.24M $23.95M $15.31M
YoY Change 102.14% 71.34% 8.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $70.00K $175.0K
YoY Change -100.0% -85.69% 75.0%
Other Long-Term Liabilities $5.483M $5.747M $4.772M
YoY Change 165.14% 150.3% 1506.73%
Total Long-Term Liabilities $5.483M $5.747M $4.772M
YoY Change 165.14% 150.3% 1506.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.24M $23.95M $15.31M
Total Long-Term Liabilities $5.483M $5.747M $4.772M
Total Liabilities $30.73M $29.70M $20.08M
YoY Change 111.09% 82.48% 39.19%
SHAREHOLDERS EQUITY
Retained Earnings -$294.8M -$259.4M -$226.5M
YoY Change 69.84% 70.69%
Common Stock $583.2M $577.0M $570.7M
YoY Change 4.39% 3.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $287.0M $316.3M $343.6M
YoY Change
Total Liabilities & Shareholders Equity $317.7M $346.0M $363.7M
YoY Change -20.52% -17.87% -15.99%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$35.32M -$32.92M -$24.53M
YoY Change 43.78% 102.29% 72.95%
Depreciation, Depletion And Amortization $95.00K $84.00K $58.00K
YoY Change 1483.33% 8300.0% 1060.0%
Cash From Operating Activities -$30.88M -$17.00M -$20.67M
YoY Change 24.25% -17.55% 302.61%
INVESTING ACTIVITIES
Capital Expenditures -$192.0K -$257.0K $589.0K
YoY Change -51.76% -8666.67% 8314.29%
Acquisitions
YoY Change
Other Investing Activities $13.89M -$75.88M -$183.3M
YoY Change
Cash From Investing Activities $13.69M -$76.13M -$183.9M
YoY Change -3540.95% -2537833.33% 2627342.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -136.0K 422.0K 80.00K
YoY Change -130.98% -42.11% -89.72%
NET CHANGE
Cash From Operating Activities -30.88M -17.00M -20.67M
Cash From Investing Activities 13.69M -76.13M -183.9M
Cash From Financing Activities -136.0K 422.0K 80.00K
Net Change In Cash -17.32M -92.71M -204.5M
YoY Change -30.19% 366.22% 4586.41%
FREE CASH FLOW
Cash From Operating Activities -$30.88M -$17.00M -$20.67M
Capital Expenditures -$192.0K -$257.0K $589.0K
Free Cash Flow -$30.69M -$16.74M -$21.26M
YoY Change 25.48% -18.81% 313.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001810182
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39386
dei Entity Registrant Name
EntityRegistrantName
ALX ONCOLOGY HOLDINGS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei City Area Code
CityAreaCode
650
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0642577
dei Local Phone Number
LocalPhoneNumber
466-7125
dei Entity Address Address Line1
EntityAddressAddressLine1
323 Allerton Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2525000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1630000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12747000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9901000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23952000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
576972000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15295000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5747000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ALXO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40747065
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66378000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363667000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
246988000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3481000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3352000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
316847000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
367019000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1630000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
897000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
10860000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16681000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12267000
CY2022Q2 us-gaap Assets
Assets
346018000
CY2021Q4 us-gaap Assets
Assets
380183000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8680000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3764000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1839000
CY2022Q2 us-gaap Liabilities
Liabilities
29699000
CY2021Q4 us-gaap Liabilities
Liabilities
17134000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40745252
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40745252
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40587067
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40587067
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
41000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
564993000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1256000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16274000
us-gaap Net Income Loss
NetIncomeLoss
-57453000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
23000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1101000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
48000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259438000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-201985000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
316319000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
346018000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
380183000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26748000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11213000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43821000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21062000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7041000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5086000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14715000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9445000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
33789000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
16299000
us-gaap Operating Expenses
OperatingExpenses
58536000
us-gaap Operating Expenses
OperatingExpenses
30507000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33789000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16299000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58536000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30507000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
876000
us-gaap Net Income Loss
NetIncomeLoss
-30459000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40687751
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40687751
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40247110
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40247110
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40652224
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40652224
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-16274000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40151802
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40151802
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-32920000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2761000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2237000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1210000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16274000
us-gaap Profit Loss
ProfitLoss
-57453000
us-gaap Profit Loss
ProfitLoss
-30459000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-650000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1256000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33570000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16274000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58709000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30459000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
185000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5501000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-606000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24533000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
343596000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
155000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
302000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5836000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-650000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
316319000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
429845000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1024000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1800000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14185000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
418484000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
464000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
103000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
405014000
us-gaap Profit Loss
ProfitLoss
-57453000
us-gaap Profit Loss
ProfitLoss
-30459000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
142000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
514000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
204000
us-gaap Share Based Compensation
ShareBasedCompensation
11337000
us-gaap Share Based Compensation
ShareBasedCompensation
4037000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-103000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
196000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
531000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
318000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
9038000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5116000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5802000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
894000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
716000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-572000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66378000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
409964000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2291000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37672000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
834000
CY2022Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
504000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2227000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25757000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
279207000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
20000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
846000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-260053000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
340000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1479000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
302000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
103000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
140000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
73000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
502000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1509000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-297223000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-24255000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363667000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
434219000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66444000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
409964000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
266000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
127000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4684000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1812000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66444000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
409964000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts in the prior period have been reclassified to conform to the current period presentation.</span></p>
CY2022Q2 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></p>
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
313053000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
357181000
CY2022Q2 us-gaap Cash
Cash
11200000
CY2021Q4 us-gaap Cash
Cash
6500000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
302193000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
357181000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
10860000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
313053000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
357181000
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2021Q2 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2022Q2 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1835000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
960000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
205000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
63000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1630000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
897000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0
CY2022Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
5000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6345000
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
499000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6083000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1829000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
522000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
746000
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
144000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
144000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
66000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16681000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12267000
CY2022Q2 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
4237000
CY2021Q4 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
4125000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3603000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3294000
CY2022Q2 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
2811000
CY2021Q4 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
693000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
646000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
458000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
790000
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
429000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
429000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
563000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12747000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9901000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6100000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
500000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
549000
CY2022Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
216000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
1246000
CY2022Q2 us-gaap Finance Lease Liability Payments Due In Next Rolling Twelve Months
FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
288000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
1273000
CY2022Q2 alxo Operating Lease Liability Current Including Payable And Accrued Liabilities Due To Related Party
OperatingLeaseLiabilityCurrentIncludingPayableAndAccruedLiabilitiesDueToRelatedParty
668000
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
429000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
1311000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
1193000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
3000000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8572000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
112000
CY2021Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
90000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
224000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
145000
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
CY2021Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5677000
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
70000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
6000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6345000
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
499000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2022Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.017
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
271000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
62000
us-gaap Operating Lease Cost
OperatingLeaseCost
520000
us-gaap Operating Lease Cost
OperatingLeaseCost
97000
CY2022Q2 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
91000
CY2021Q2 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
17000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
143000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
39000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
83000
CY2022Q2 us-gaap Lease Cost
LeaseCost
515000
CY2021Q2 us-gaap Lease Cost
LeaseCost
172000
us-gaap Lease Cost
LeaseCost
975000
us-gaap Lease Cost
LeaseCost
287000
us-gaap Operating Lease Payments
OperatingLeasePayments
429000
us-gaap Operating Lease Payments
OperatingLeasePayments
102000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
140000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
73000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4684000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1812000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
834000
us-gaap Net Income Loss
NetIncomeLoss
-57453000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40745252
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40587067
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11213603
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5836000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2237000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11337000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4037000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16274000
us-gaap Net Income Loss
NetIncomeLoss
-30459000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40687751
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40687751
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40247110
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40247110
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40652224
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40652224
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40151802
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40151802
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5724925
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4421243
CY2022Q2 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0

Files In Submission

Name View Source Status
0000950170-22-015553-index-headers.html Edgar Link pending
0000950170-22-015553-index.html Edgar Link pending
0000950170-22-015553.txt Edgar Link pending
0000950170-22-015553-xbrl.zip Edgar Link pending
alxo-20220630.htm Edgar Link pending
alxo-20220630.xsd Edgar Link pending
alxo-ex31_1.htm Edgar Link pending
alxo-ex31_2.htm Edgar Link pending
alxo-ex32_1.htm Edgar Link pending
alxo-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
alxo-20220630_def.xml Edgar Link unprocessable
alxo-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alxo-20220630_pre.xml Edgar Link unprocessable
alxo-20220630_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
alxo-20220630_cal.xml Edgar Link unprocessable